(Q50938799)

English

Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome.

scientific article published on 29 July 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

population-based cohort study

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hanneke C Kluin-Nelemans

10

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

author name string

Karin Boslooper

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Robby Kibbelaar

2

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Huib Storm

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Nic J G M Veeger

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Sjoerd Hovenga

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Gerhard Woolthuis

6

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Bas van Rees

7

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Elly de Graaf

8

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Eric van Roon

9

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Peter Joosten

11

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Mels Hoogendoorn

12

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

publication date

29 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

55

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

526-532

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

How I treat elderly patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Management of elderly patients with hematological neoplasms.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.810737

21 January 2018

Identifiers

10.3109/10428194.2013.810737

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23734653

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50938799&oldid=1561106008"